Results 171 to 180 of about 4,521 (193)

P0700 Impact of filgotinib on health-related quality of life over 3 years in Japanese patients with Ulcerative Colitis: A post hoc analysis of the SELECTION and SELECTION long-term extension trials

Journal of Crohn's & Colitis
Filgotinib (FIL) is an oral, once-daily, Janus kinase 1 preferential inhibitor approved for the treatment of ulcerative colitis (UC). The efficacy and safety of FIL in adults with moderately to severely active UC were evaluated in the phase 2b/3 ...
K. Matsuoka, S. Schreiber, E. Hata, T. Kaise, T. Hibi   +4 more
semanticscholar   +1 more source

Filgotinib for the Treatment of Refractory Collagenous Colitis

Journal of Crohn's and Colitis, 2023
Tomoyoshi Shibuya, Akihito Nagahara
openaire   +2 more sources

Filgotinib for ulcerative colitis

Nature Reviews Gastroenterology & Hepatology, 2021
openaire   +2 more sources

Filgotinib/prednisolone

Reactions Weekly, 2023
openaire   +1 more source

Filgotinib Induces and Maintains Ulcerative Colitis Remission

JAMA, 2021
openaire   +2 more sources

Le filgotinib (Jyseleca®), un inhibiteur des Janus kinases

Actualités Pharmaceutiques, 2022
Jacques Buxeraud, Sébastien Faure
openaire   +1 more source

Rheumatoide Arthritis: Filgotinib mit gutem Sicherheitsprofil

Orthopädie & Rheuma, 2021
openaire   +1 more source

Dose-dependent efficacy and safety of Filgotinib in moderate to severe Crohn’s disease: a grade-assessed systematic review and meta-analysis of randomized controlled trials

European Journal of Clinical Pharmacology
M. Elgendy, Ahmed Raza, Mohamed Rifai, W. Rehman, Ahmed Emara, Muhammad Haris Khan, Ayiz Jan, Muhammad Younas, Anum Nawaz, Ubaid Khan   +9 more
semanticscholar   +1 more source

RA mit Filgotinib früh, wirksam und sicher behandeln

Orthopädie & Rheuma, 2021
openaire   +1 more source

Filgotinib for Crohn's disease—expanding treatment options

The Lancet, 2017
openaire   +2 more sources